To complete the picture of the importance of autophagic blockage in the treatment of tumours, we compared the results using our most potent autophagy inhibitor, tenovin-50, with a current treatment against melanoma, the B-Raf inhibitor vemurafenib. The gene discussed is BRAF; the disease is neoplasm.